Dr Martin Falk studied chemistry with a focus on biochemistry in Mainz and Freiburg and received his doctorate in 1999 from the Chair of Pharmaceutical Technology in Freiburg.

In the following years until the end of 2003, he worked, among others, as a consultant in the healthcare practice of Arthur D. Little in Zurich and London.

From 2004 to 2009, he served as managing director of Dr. Falk Pharma and chairman of the Falk Foundation e.V. Following this, Dr Martin Falk was managing partner of Benevi Med until 2022 and has also been a board member and shareholder of Dr. Falk Pharma since 2017. In addition, he has again been chairman of the Falk Foundation e.V. since 2020.

Since 2018, he has been managing director of the single-family office Acondis GmbH. One pillar of the investment strategy that Dr Martin Falk continues to drive forward are investments in the field of venture capital.

Seit 2018 ist er Geschäftsführer des Single-Family-Office Acondis GmbH. Eine Säule der Investitionsstrategie, die Dr. Martin Falk weiter vorantreibt, sind Investitionen im Bereich Venture Capital.